{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:04:58Z","timestamp":1793639098880,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University Hospital in Ostrava"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In relapsed\/refractory (RR) chronic lymphocytic leukaemia (CLL), Bruton tyrosine kinase inhibitors (BTKi) are administered as monotherapy until disease progression. In contrast, venetoclax, a B-cell lymphoma 2 (BCL-2) protein inhibitor, is typically combined with rituximab (VenR) as a time-limited regimen. To date, neither randomized nor retrospective trials have directly compared these approaches in RR CLL, and only limited data are available comparing venetoclax plus obinutuzumab (VenObi) to BTKi in the first-line setting. We retrospectively analysed 352 patients receiving second-line therapy: 93 VenR and 259 BTKi (ibrutinib:\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009222; acalabrutinib:\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200937). Baseline characteristics were well balanced, except for a higher incidence of\n                    <jats:italic>TP53<\/jats:italic>\n                    mutation and trisomy 12 in BTKi-treated patients. At a median follow-up of 13.8 months (VenR) and 22.1 months (BTKi), 12-month progression-free survival (PFS) and overall survival (OS) were comparable (PFS: 85.1% vs. 82.2%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.265; OS: 87.6% vs. 88.4%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.291). Estimated median PFS (45.4 vs. 37.9 months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.265) and OS (83.6 vs. 74.2 months,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.291) also showed no significant differences between the VenR and BTKi cohorts. Treatment discontinuation due to adverse events before month 24 was more frequent with BTKi (22.5% with VenR vs. 34.3% with BTKi), primarily due to infections (10.6% vs. 28.6%) and disease progression (14.3% vs. 22.5%). These preliminary data suggest comparable outcomes and manageable toxicity profiles for both regimens.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07043-8","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:46:41Z","timestamp":1778626001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-7873","authenticated-orcid":false,"given":"Jana","family":"Mih\u00e1lyov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-3039","authenticated-orcid":false,"given":"Anna","family":"Panovsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-5334","authenticated-orcid":false,"given":"Martin","family":"\u0160imkovi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-8595","authenticated-orcid":false,"given":"Luk\u00e1\u0161","family":"Smolej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5250-8218","authenticated-orcid":false,"given":"Martin","family":"\u0160pa\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Shokralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Kubov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Zuchnick\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5198-0307","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Arp\u00e1\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8050-7594","authenticated-orcid":false,"given":"Pavel","family":"Vod\u00e1rek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-3841","authenticated-orcid":false,"given":"Peter","family":"Turcs\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3034-9599","authenticated-orcid":false,"given":"Lenka","family":"Polcerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Chr\u00e1pav\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9391-4247","authenticated-orcid":false,"given":"Daniel","family":"Lys\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Brejcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2034-0769","authenticated-orcid":false,"given":"Heidi","family":"M\u00f3cikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1269-6282","authenticated-orcid":false,"given":"Michael","family":"Doubek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"7043_CR1","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","volume":"36","author":"A Agathangelidis","year":"2022","unstructured":"Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T et al (2022) Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. Leukemia 36:1961\u20131968. https:\/\/doi.org\/10.1038\/s41375-022-01604-2","journal-title":"Leukemia"},{"key":"7043_CR2","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.2217\/fon-2023-0535","volume":"19","author":"G Ayoub","year":"2023","unstructured":"Ayoub G, Sinan H, Kourie HR et al (2023) Genetic markers of chronic lymphocytic leukemia: a retrospective study of 312 patients from a reference center in Lebanon. Future Oncol 19:1991\u20132002. https:\/\/doi.org\/10.2217\/fon-2023-0535","journal-title":"Future Oncol"},{"key":"7043_CR3","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","volume":"35","author":"B Eichhorst","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU et al (2024) ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia\u2606. Ann Oncol 35:762\u2013768. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.016","journal-title":"Ann Oncol"},{"key":"7043_CR4","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398","journal-title":"Blood"},{"key":"7043_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S et al (2014) Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. N Engl J Med 371:213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1400376","journal-title":"N Engl J Med"},{"key":"7043_CR6","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S et al (2019) Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94:1353\u20131363. https:\/\/doi.org\/10.1002\/ajh.25638","journal-title":"Am J Hematol"},{"key":"7043_CR7","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1182\/blood.2024024667","volume":"144","author":"JR Brown","year":"2024","unstructured":"Brown JR, Eichhorst B, Lamanna N et al (2024) Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE. Blood 144:2706\u20132717. https:\/\/doi.org\/10.1182\/blood.2024024667","journal-title":"Blood"},{"key":"7043_CR8","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","volume":"6","author":"P Ghia","year":"2022","unstructured":"Ghia P, Pluta A, Wach M et al (2022) Acalabrutinib Versus Investigator\u2019s Choice in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. Hemasphere 6:e801. https:\/\/doi.org\/10.1097\/HS9.0000000000000801","journal-title":"Hemasphere"},{"key":"7043_CR9","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J et al (2019) Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 380:2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1815281","journal-title":"N Engl J Med"},{"key":"7043_CR10","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","volume":"24","author":"CU Niemann","year":"2023","unstructured":"Niemann CU, Munir T, Moreno C et al (2023) Fixed-duration ibrutinib\u2013venetoclax versus chlorambucil\u2013obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24:1423\u20131433. https:\/\/doi.org\/10.1016\/S1470-2045(23)00452-7","journal-title":"Lancet Oncol"},{"key":"7043_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR et al (2023) Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med 389:33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2300696","journal-title":"N Engl J Med"},{"key":"7043_CR12","doi-asserted-by":"publisher","first-page":"S352","DOI":"10.1016\/S2152-2650(24)01278-3","volume":"24","author":"T Tadmor","year":"2024","unstructured":"Tadmor T, Eyre TA, Benjamini O et al (2024) CLL-414 Phase 3 BELLWAVE-011 Study: Nemtabrutinib Versus Ibrutinib or Acalabrutinib in Previously Untreated Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (SLL). Clin Lymphoma Myeloma Leuk 24:S352\u2013S353. https:\/\/doi.org\/10.1016\/S2152-2650(24)01278-3","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7043_CR13","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO-25-00166","volume":"43","author":"JP Sharman","year":"2025","unstructured":"Sharman JP, Munir T, Grosicki S et al (2025) Phase III Trial of Pirtobrutinib Versus Idelalisib\/Rituximab or Bendamustine\/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor\u2013Pretreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (BRUIN CLL-321). J Clin Oncol 43:2538\u20132549. https:\/\/doi.org\/10.1200\/JCO-25-00166","journal-title":"J Clin Oncol"},{"key":"7043_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","volume":"19","author":"JA Jones","year":"2018","unstructured":"Jones JA, Mato AR, Wierda WG et al (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(17)30909-9","journal-title":"Lancet Oncol"},{"key":"7043_CR15","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J et al (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17:768\u2013778. https:\/\/doi.org\/10.1016\/S1470-2045(16)30019-5","journal-title":"Lancet Oncol"},{"key":"7043_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P et al (2019) Fixed Duration of Venetoclax-Rituximab in Relapsed\/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol 37:269\u2013277. https:\/\/doi.org\/10.1200\/JCO.18.01580","journal-title":"J Clin Oncol"},{"key":"7043_CR17","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B et al (2018) Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 378:1107\u20131120. https:\/\/doi.org\/10.1056\/NEJMoa1713976","journal-title":"N Engl J Med"},{"key":"7043_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","volume":"140","author":"JF Seymour","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF et al (2022) Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood 140:839\u2013850. https:\/\/doi.org\/10.1182\/blood.2021015014","journal-title":"Blood"},{"key":"7043_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P et al (2021) Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.21.01210","journal-title":"J Clin Oncol"},{"key":"7043_CR20","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","volume":"56","author":"F Salvi","year":"2008","unstructured":"Salvi F, Miller MD, Grilli A et al (2008) A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 56:1926\u20131931. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01935.x","journal-title":"J Am Geriatr Soc"},{"key":"7043_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/10428194.2016.1180690","volume":"58","author":"H Plesingerova","year":"2017","unstructured":"Plesingerova H, Librova Z, Plevova K et al (2017) COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. Leuk Lymphoma 58:70\u201379. https:\/\/doi.org\/10.1080\/10428194.2016.1180690","journal-title":"Leuk Lymphoma"},{"key":"7043_CR22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/s41375-024-02267-x","volume":"38","author":"J Malcikova","year":"2024","unstructured":"Malcikova J, Pavlova S, Baliakas P et al (2024) ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update. Leukemia 38:1455\u20131468. https:\/\/doi.org\/10.1038\/s41375-024-02267-x","journal-title":"Leukemia"},{"key":"7043_CR23","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach JA, Ruppert AS, Guinn D et al (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437\u20131443. https:\/\/doi.org\/10.1200\/JCO.2016.70.2282","journal-title":"J Clin Oncol"},{"key":"7043_CR24","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","volume":"6","author":"P Blombery","year":"2022","unstructured":"Blombery P, Thompson ER, Lew TE et al (2022) Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv 6:5589\u20135592. https:\/\/doi.org\/10.1182\/bloodadvances.2022008325","journal-title":"Blood Adv"},{"key":"7043_CR25","doi-asserted-by":"publisher","first-page":"9847","DOI":"10.1182\/blood-2022-159525","volume":"140","author":"C Sun","year":"2022","unstructured":"Sun C, Acar M, Jenkins D et al (2022) Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression. Blood 140:9847\u20139848. https:\/\/doi.org\/10.1182\/blood-2022-159525","journal-title":"Blood"},{"key":"7043_CR26","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery P, Anderson MA, Gong J et al (2019) Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discov 9:342\u2013353. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1119","journal-title":"Cancer Discov"},{"key":"7043_CR27","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","volume":"140","author":"D Thomalla","year":"2022","unstructured":"Thomalla D, Beckmann L, Grimm C et al (2022) Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood 140:2113\u20132126. https:\/\/doi.org\/10.1182\/blood.2021014304","journal-title":"Blood"},{"key":"7043_CR28","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M et al (2020) ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 38:2849\u20132861. https:\/\/doi.org\/10.1200\/JCO.19.03355","journal-title":"J Clin Oncol"},{"key":"7043_CR29","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF et al (2017) Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed\/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Blood 130:LBA-2-LBA-2","DOI":"10.1182\/blood.V130.Suppl_1.LBA-2.LBA-2"},{"key":"7043_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjh.18736","volume":"202","author":"M \u0160pa\u010dek","year":"2023","unstructured":"\u0160pa\u010dek M, Smolej L, \u0160imkovi\u010d M et al (2023) Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed\/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR). Br J Haematol 202:40\u201347. https:\/\/doi.org\/10.1111\/bjh.18736","journal-title":"Br J Haematol"},{"key":"7043_CR31","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC et al (2018) Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica 103:874\u2013879. https:\/\/doi.org\/10.3324\/haematol.2017.182907","journal-title":"Haematologica"},{"key":"7043_CR32","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1182\/blood-2023-174974","volume":"142","author":"RW Jacobs","year":"2023","unstructured":"Jacobs RW, Teschemaker A, Hakre S et al (2023) Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment By Line of Therapy in Patients with Chronic Lymphocytic Leukemia and\/or Small Lymphocytic Lymphoma. Blood 142:5151. https:\/\/doi.org\/10.1182\/blood-2023-174974","journal-title":"Blood"},{"key":"7043_CR33","doi-asserted-by":"publisher","first-page":"12395","DOI":"10.1182\/blood-2022-162319","volume":"140","author":"L Ysebaert","year":"2022","unstructured":"Ysebaert L, Troussard X, Levy V et al (2022) Real-World Efficacy and Safety of Venetoclax Alone and in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia: Interim Results of the Verone Study. Blood 140:12395\u201312396. https:\/\/doi.org\/10.1182\/blood-2022-162319","journal-title":"Blood"},{"key":"7043_CR34","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood-2021-148696","volume":"138","author":"L Scarfo","year":"2021","unstructured":"Scarfo L, Albi E, Quaglia FM et al (2021) An Observational Study on Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). Blood 138:3746. https:\/\/doi.org\/10.1182\/blood-2021-148696","journal-title":"Blood"},{"key":"7043_CR35","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s00277-023-05304-4","volume":"102","author":"A Sobo\u0144","year":"2023","unstructured":"Sobo\u0144 A, Drozd-Soko\u0142owska J, Paszkiewicz-Kozik E et al (2023) Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia\u2014a real-world analysis of the Polish Adult Leukemia Study Group. Ann Hematol 102:2119\u20132126. https:\/\/doi.org\/10.1007\/s00277-023-05304-4","journal-title":"Ann Hematol"},{"key":"7043_CR36","unstructured":"Coombs Catherine, Roeker L, Rhodes J, Mazyar Shadman (2024) REAL-WORLD TREATMENT EFFECTIVENESS IN HIGH-RISK PATIENTS WITH\u2026 by Catherine C. Coombs. In: EHA 2024. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/420729\/catherine.c.coombs.real-world.treatment.effectiveness.in.high-risk.patients.html.Accessed 30 Jan 2025"},{"key":"7043_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27563","author":"N Ghosh","year":"2024","unstructured":"Ghosh N, Eyre TA, Brown JR et al (2024) Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.27563","journal-title":"Am J Hematol"},{"key":"7043_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2019.241539","volume":"106","author":"TA Eyre","year":"2020","unstructured":"Eyre TA, Lamanna N, Roeker LE et al (2020) Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia. Haematologica 106:284\u2013287. https:\/\/doi.org\/10.3324\/haematol.2019.241539","journal-title":"Haematologica"},{"key":"7043_CR39","doi-asserted-by":"crossref","unstructured":"Lamanna N (2024) Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL. An International Real-World Study. ASH","DOI":"10.1182\/blood-2024-205223"},{"key":"7043_CR40","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","volume":"133","author":"JC Byrd","year":"2019","unstructured":"Byrd JC, Hillmen P, O\u2019Brien S et al (2019) Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 133:2031\u20132042. https:\/\/doi.org\/10.1182\/blood-2018-08-870238","journal-title":"Blood"},{"key":"7043_CR41","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K et al (2019) Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. J Clin Oncol 37:2722\u20132729. https:\/\/doi.org\/10.1200\/JCO.19.00894","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07043-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07043-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07043-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:23Z","timestamp":1786785623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07043-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["7043"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07043-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved by the independent ethics committees at each site (Ethics Committee of the University Hospital Ostrava; Ethics Committee of the University of Ostrava; Ethics Committee of the University Hospital Brno and Faculty of Medicine, Masaryk University; Ethics Committee of the University Hospital Hradec Kr\u00e1lov\u00e9 and Faculty of Medicine in Hradec Kr\u00e1lov\u00e9; Ethics Committee of the General University Hospital in Prague and First Faculty of Medicine; Ethics Committee of the University Hospital Olomouc and Faculty of Medicine and Dentistry; Ethics Committee of the Medical School and Teaching Hospital in Plze\u0148; Ethics Committee of Hospital Agel, Nov\u00fd Ji\u010d\u00edn; Ethics Committee of the University Hospital Kr\u00e1lovsk\u00e9 Vinohrady and Third Faculty of Medicine).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tom\u00e1\u0161 Arp\u00e1\u0161: none; Martin Brejcha: consultancy, conference sponsorship: AbbVie, AstraZeneca, Janssen; Michael Doubek: consultancy, honoraria, conference sponsorship: AbbVie, AstraZeneca, AOP Orphan, Bristol Myers Squibb, Janssen, Novartis; Marika Chr\u00e1pav\u00e1: none; Zuzana Kubov\u00e1: none; Daniel Lys\u00e1k: consultancy, honoraria, travel grants: Janssen, AbbVie, AstraZeneca, Novartis; Jana Mih\u00e1lyov\u00e1: consultancy, honoraria, conference sponsorship: AbbVie, Janssen, Novartis; Heidi M\u00f3cikov\u00e1: none; Anna Panovsk\u00e1: honoraria, travel grants: AstraZeneca, Gilead, Janssen, AbbVie; Lenka Polcerov\u00e1: none; Luk\u00e1\u0161 Smolej: honoraria, advisory board membership, travel grants: AbbVie, AstraZeneca, Janssen, Roche; Tereza Shokralla: Conference sponsorship: Janssen, Abbvie, Astra Zeneca; Martin \u0160imkovi\u010d: honoraria, advisory board membership, travel grants: AbbVie, AstraZeneca, Janssen; Martin \u0160pa\u010dek: consultancy, honoraria, conference sponsorship: AbbVie, AstraZeneca, BeiGene, Johnson&Johnson, Eli Lilly, Swixx Biopharma; Peter Turcs\u00e1nyi: none; Pavel Vod\u00e1rek: none; Jana Zuchnick\u00e1: none.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"326"}}